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Abstract 
Imitation plays a key role in social learning and in facilitating social interactions and likely constitutes a basic 
building block of social cognition that supports higher-level social abilities. Recent findings suggest that 
patients with schizophrenia have imitation impairments that could contribute to the social impairments 
associated with the disorder. However, extant studies have specifically assessed voluntary imitation or 
automatic imitation of emotional stimuli without controlling for potential confounders. The imitation 
impairments seen might therefore be secondary to other cognitive, motoric or emotional deficits 
associated with the disorder. To overcome this issue, we used an automatic imitation paradigm with non-
emotional stimuli to assess automatic imitation and the top-down modulation of imitation where 
participants were required to lift one of two fingers according to a number shown on the screen whilst 
observing the same or the other finger movement. In addition, we used a control task with a visual cue in 
place of a moving finger, to isolate the effect of observing finger movement from other visual cueing 
effects. Data from 33 patients (31 medicated) and 40 matched healthy controls were analyzed. Patients 
displayed enhanced imitation and intact top-down modulation of imitation. The enhanced imitation seen in 
patients may have been medication induced as larger effects were seen in patients receiving higher 
antipsychotic doses. In sum, we did not find an imitation impairment in schizophrenia. The results suggest 
that previous findings of impaired imitation in schizophrenia might have been due to other cognitive, 
motoric and/or emotional deficits. 
 
Keywords: social influence, social cognition, mimicry, top-down control, antipsychotic medication
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Introduction 
Imitation refers to the translation of perceived actions into executed actions1. Imitation is a likely 
foundation for important social behaviors, ranging from social learning (e.g. skill or language acquisition) to 
the ability to understand the intentions and feelings of others2. Imitation also contributes to smoothness, 
predictability, and feelings of affiliation in social interactions3, 4. As such, research on imitation is crucial for 
understanding disorders that are characterized by impairments in social behavior, and may provide a better 
understanding of the underlying deficits involved in such conditions.  
Patients with schizophrenia (SCZ) display impairments that may involve imitation-related systems, including 
understanding the intentions and feelings of others5 and they tend to have difficulties with social 
interactions6. Behavioral studies on imitation in schizophrenia suggest that patients are impaired at 
imitating others7-12 and it has been suggested that schizophrenia constitutes a disorder of imitation13. 
However, there is clear heterogeneity between studies when looking at the biological foundations of the 
impairment. Some imaging and transcranial magnetic stimulation (TMS) studies find intact activity14-17 in 
the mirror neuron system (MNS)1 – which is thought to form the neural basis of imitation18-21 - during action 
observation and execution; while others find this activity to be reduced22, 23, altered13 or enhanced14, 24 .  
Several issues also remain unresolved with respect to the behavioral studies. Experimental work within this 
area can be roughly categorized into four domains: imitation can either be voluntary or automatic, and it 
can be of either emotional (e.g. facial expressions) or non-emotional stimuli (e.g. manual movements). 
Studies have primarily focused on voluntary imitation where participants e.g. are required to imitate 
certain movements. This research has consistently shown that patients make more errors when asked to 
imitate facial and manual movements8-10, 25-28 and facial expressions7, 10, 26, 29-31 compared to healthy 
individuals.  
                                                            
1 Core MNS circuitry: the pars opercularis of the inferior frontal gyrus and adjacent ventral premotor cortex (Brodmann area 44 and 
6) and the rostral inferior parietal lobule as well as the superior temporal sulcus, which processes biological motion. 
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Meanwhile, research on automatic imitation has been limited, in particular when it comes to imitation of 
non-emotional stimuli. Such research is important for three main reasons. First, voluntary tasks are (to 
varying degrees) taxing on a range of cognitive processes which are known to be impaired in 
schizophrenia32,  but which are not specifically tied to imitation. For instance, voluntary imitation requires 
working memory, attention to detail, planning, and self-monitoring of accuracy. It is therefore unclear 
whether the imitation impairments seen are due to specific imitation deficits, or due to general cognitive 
deficits which, among other things, should also be expected to impact voluntary imitation. Automatic 
processes, on the other hand, are generally much less taxing on such cognitive processes.33 
Second, assessing someone’s ability to voluntarily imitate is not the same as assessing their tendency to 
imitate or potential difficulties in the ability to inhibit involuntary imitation. This is important, because 
reduced imitation tendency may result in worse social interactions3 while over-imitation may result in 
catatonic symptoms like echolalia or echopraxia seen in schizophrenia34, 35. The top down modulation of 
imitation and the MNS is subserved by structures related to perspective taking or mentalizing (including 
medial prefrontal cortex (mPFC) and temporo-parietal junction (TPJ)) as well as structures related to 
general cognitive control processes. Imitation-inhibition and general inhibition processes are thus thought 
to be at least partially distinct36-44  . Interestingly, reduced top-down modulation of imitation has also been 
associated with reduced mentalizing and perspective-taking ability36, 40, abilities known to be impaired in 
schizophrenia45.  
Third, because patients display a variety of problems in processing of emotions46, it is unclear whether a 
deficit in voluntary or automatic imitation of emotional stimuli11, 12, 47, 48 would reflect a specific impairment 
in imitation, or other aspects of emotion processing: e.g. differences in visual processing of faces (avoiding 
salient regions like the eyes and the mouth)49, the experience of emotional states, or emotional reactions 
to the stimuli50. For instance, a characteristic symptom in schizophrenia is  blunted affect29, 51. This makes it 
difficult to distinguish between direct effects of action observation on action execution (imitation) and 
those mediated by emotional states. 
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Automatic imitation of non-emotional stimuli has not been studied experimentally in patients with 
schizophrenia and would overcome the limitations mentioned above. We therefore set out to investigate 
whether the basic mechanisms of imitation, and the top-down modulation of these (imitation-inhibition) is 
altered in schizophrenia, compared to healthy individuals.  
Participants were asked to perform an automatic imitation task52, where they performed certain finger 
movements according to the number shown on a screen, whilst observing the same or another finger move 
on the screen. Although the performed finger movements are voluntary, any effect of imitation on these is 
accidental since participants are not instructed to imitate, and general imitation results in poorer task 
performance. By assessing automatic processes we effectively reduce the cognitive load; however, lower 
level attentional processes are still recruited and may be affected in schizophrenia. We therefore  included 
a control task52 to be able to delineate imitation and imitation-inhibition from any attentional deficits or 
deficits in distractor-inhibition (for detailed task description see Methods). This also allowed us to control 
for any motor deficits. 
We predicted that patients would have slower reaction times (RTs) and make more errors than healthy 
individuals, since patients display cognitive32 and motor deficits53 (e.g., psychomotor slowing/reduced 
processing speed54). Importantly, we had four core research questions (i – iv), we wanted to answer: we 
were interested in determining whether patients would show deficits beyond those that could be 
attributed merely to other cognitive or motoric deficits, indicating a specific deficit in either i) basic 
imitation or ii) the top-down control of it (i.e. imitation-inhibition). In addition, since two recent studies13, 22 
indicate that antipsychotic medication might normalize putative mirror neuron activity (MNA) during action 
observation and imitation, we assessed whether iii) imitation or iv) imitation-inhibition tendency in patients 
was associated with antipsychotic medication dose. Finally, in case of group differences in imitation or 
imitation-inhibition, we were interested in assessing whether these were associated with the patients’ level 
of functioning. 
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Methods 
Participants 
Thirty-nine patients with an ICD-10 DCR diagnosis of schizophrenia or schizoaffective disorder and forty 
matched healthy controls were included in the study. Diagnosis was confirmed using the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN)55, 56. Controls were pairwise matched to the patients 
according to age, gender, childhood residence as well as commenced educational level and parental 
socioeconomic status when possible (see Table 1). Two of the controls were matched to patients that had 
to be excluded as they did not fulfil inclusion criteria and one patient did not have a matched control as 
they did not complete the whole study. 
Patients were recruited through the Psychiatric Centre of the National Hospital of the Faroe Islands. 
Controls were contacted based on their age and gender and, if they fulfilled the inclusion criteria and 
matched a patient, were offered to participate in the study. Participants were between 18 and 55 years old. 
Exclusion criteria included: current psychoactive substance use disorders (except nicotine), a neurological 
or medical disorder that could affect brain functioning, and an estimated IQ below 70 based on prior 
history or testing. In addition, the controls were excluded if they or a first-degree relative had a history of 
severe mental disorder. The participants were screened for recent use of psychoactive substances 
(THC/cannabis, opiates, amphetamine, MDMA, benzodiazepines, cocaine) using a urine stick (NanoSticka® 
200-32). Patients, without a prescription who had a positive test, were excluded. None of the controls had 
a positive test. At the time of testing, all but two patients were taking antipsychotic medication. We 
converted antipsychotic doses to chlorpromazine (CPZ) equivalents57, 58 (see Table 1S for details). Some 
patients also took other types of medication (see Table 2S). 
Six patients had hand tremor which made it difficult or impossible for them to keep their fingers stable 
enough to complete the task. Data from these was excluded from the analysis. Data from 33 patients and 
40 controls were included in the analysis.  
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General Procedure 
The imitation task was administered as part of a larger battery of cognitive tasks. In addition, symptom 
severity and level of functioning were assessed with the Scale for the Assessment of Positive/Negative 
Symptoms (SAPS/SANS)51, 59 and the Personal and Social Performance Scale (PSP)60, respectively (see Table 
1). The study complied with the ethical standards of the relevant national and institutional committees and 
with the Helsinki Declaration. Written informed consent was obtained from all participants after the 
procedure had been explained. 
 
Imitation and Effector Priming Control Task 
The task is a modified version of the automatic imitation and effector priming control tasks described in 
Cook & Bird (2011)52. Briefly, short video sequences of a human hand were presented on a computer 
screen (see Figure 1) comprising 4 different conditions in a 2 x 2 factorial design with the factors task 
(imitation or control) and congruency between the targeted finger on the screen and the required finger 
movement (congruent or incongruent finger). There were 120 trials in total, 30 for each condition.   
Participants were required to place the index and middle fingers of their right hand on the number 1 and 2 
(letter N and M on the keyboard), respectively. On each trial, participants had to lift either their index or 
middle finger as fast as possible according to the number shown on the screen and then replace it on the 
same key: if “1” was shown, they had to lift their index finger and if “2” was shown, they had to lift their 
middle finger. 
In the imitation task (see Figure 1a) half of the trials depicted an action that was congruent with the 
required finger movement (e.g. index finger lift required and index finger lift shown) and the other half 
were incongruent. Similarly, in the control task (see Figure 1b), on half of the trials a semi-transparent 
green mask appeared on the finger corresponding to the instructed finger movement (congruent trials), 
and on the other half the mask appeared on the opposite finger (incongruent trials, e.g. index finger lift 
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required and mask appeared on the middle finger). During the control task the fingers remained still for the 
whole trial. Trials were pseudo-randomized so that the same trial type never occurred more than twice in a 
row. In order to differentiate automatic imitation from spatial compatibility52, response movements were 
orthogonal to stimulus postures (see Figure 1). The task was programmed in Presentation v. 16.3 
(Neurobehavioral Systems). 
Before the testing, participants were given standardized instructions and a practice session where they had 
to make 8 correct responses in a row to ensure their ability to perform the task. The whole process took 
approximately 15 min. 
 
Data Analysis 
As in Cook & Bird (2011)52, RTs shorter than 150 ms and longer than 2.000 ms were excluded from the 
analysis. In addition, error-trials in which the participant lifted the incorrect finger were removed from the 
RT analyses. All analyses were run using mixed effects regression models. To assess whether there was a 
specific imitation (question i) or imitation-inhibition (question ii) deficit in schizophrenia beyond non-
specific cognitive or motoric deficits, we ran two separate models with RTs as outcome and group 
(schizophrenia, control) by task (imitation, control) as predictors, including only congruent trials to answer 
question i and only incongruent trials to answer question ii (see Table 2). The analyses accounted for the 
pairwise matching of participants (when present), by assigning the matched individuals a common 
identifier and entering it as a random intercept. Random slopes were included for group, task and finger 
(index vs. middle finger).  
To assess whether there was an association between antipsychotic medication dose and imitation 
(question iii) or imitation-inhibition (question iv), we ran two separate models in the patients only with RTs 
as outcome and medication dose by task (imitation, control) as predictors, including only congruent trials to 
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answer question iii and only incongruent trials to answer question iv (see Table 3). Random slopes were 
included for task and finger.  
Finally, follow up control analyses were run to assess whether a potential group difference could be due to 
generally slower RTs in patients (Table 6S patients, 7S controls) and whether any medication effects would 
still hold when excluding patients with recent antipsychotic medication changes and when controlling for 
potential confounders such as other medications (Table 8S), symptom severity (Table 9S) or level of 
functioning (Table 10S). Here we also assessed whether a group difference in imitation or imitation-
inhibition was associated with level of functioning in the patients (Table 10S). A full description of these 
models as well as the models assessing that the task worked as expected can be found in the 
Supplementary Material Tables 4S – 10S. Note, that effect sizes are reported in the form of standardized 
beta coefficients for all linear models. In case of null results on theoretically meaningful comparisons, we 
performed a follow-up Bayes Factor (BF) analysis on the mixed effects models to assess the evidence in 
favor of the null hypothesis, with values below 0.3 indicating substantial evidence in favor of the null. For a 
more detailed explanation of mixed effects models, BF and the computational implementation, cf. 
Supplementary Material.  
 
Results 
Errors and Reaction Times 
As predicted, patients made more errors than controls (SCZ: 8.79%, M = 10.55, SD = 7.47; controls: 5.27%, 
M = 6.33, SD = 6.44). This was the case for all three types of errors: wrong finger lifted (β = 0.61, SE = 0.16, z 
= 3.74, p < 0.001), RTs shorter than 150 ms (β = 0.98, SE = 0.23, z = 4.34, p < 0.001), and RTs longer than 
2000 ms (β = 0.29, SE = 0.13, z = 2.27, p = 0.023). Patients also displayed slower RTs across conditions 
compared to controls (SCZ: M = 592 ms per trial, SD = 114.97; controls: M = 534.91 ms, SD = 62.66; β = 0.37, 
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SE = 0.14, t = 2.73, p = 0.01). For details on the error rate for each type of error by condition and group, see 
Table 3S. 
 
Imitation Effect: Movement Facilitation due to Imitation vs a Control Cue 
When assessing imitation in the two groups (question i), we compared RTs (outcome) in the two tasks 
(imitation, control) by group (predictors), looking at congruent trials only. Controls responded significantly 
faster to imitation trials compared to control trials. In addition, there was a significant interaction between 
task and group on RT (see Table 2: congruent trials). Specifically, patients showed an even larger difference 
in RTs between imitation and control trials than the healthy controls, see Figure 2a.  
To assess whether this larger difference seen in the patients could be due to their generally slower RTs, we 
assessed the interaction between mean RT during congruent control trials and task (imitation vs control) in 
the two groups separately. For the patients, there was a significant interaction, where the slower the RT, 
the larger the difference between imitation trials and control trials (β = -0.25, SE = 0.08, t = -3.22, p = 0.002, 
Table 6S). In contrast, there was no such relationship in the controls (β = 0.07, SE = 0.10, t = 0.65, p = 0.518, 
BF = 0.07, Table 7S). 
 
Imitation-Inhibition Effect: Inhibition of Imitation vs a Control Distractor Cue 
Next, we looked at whether the groups responded differently to imitation-inhibition vs distractor-inhibition 
(question ii), by comparing incongruent trials in the two tasks. Controls had similar RTs during inhibition of 
imitation and distractor cue (BF < 0.001) and there was no significant interaction between task and group 
(BF = 0.07, Table 2: incongruent trials), see Figure 2b. 
 
Imitation Tendency, Antipsychotic Medication Dose and Level of Functioning 
Finally, we assessed the influence of antipsychotic medication dose on imitation (question iii) and imitation-
inhibition (question iv). We first looked at congruent trials in the two tasks (imitation, control) for the 
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patients (question iii). We observed a significant interaction between task and medication dose on RTs. 
Specifically, patients receiving a higher dose showed faster RTs during imitation vs control trials (see Table 
3: congruent trials).  This effect could not be easily explained by slower RTs in patients receiving higher 
doses, as there was no significant association between RT on congruent control trials and medication dose 
(β = 0.17, SE = 0.14, t = 1.2, p = 0.24, BF = 0.46). The interaction between task and medication dose 
remained significant when excluding the four patients, who had changes made in their antipsychotic 
medication within the last 3 weeks prior to testing and adjusting for other types of medication (Table S8), 
for symptom severity (Table S9) or for level of functioning (Table S10). Note, that there was an interaction 
between level of functioning and task in this last model, i.e. the higher the level of functioning, the faster 
RTs during imitation vs control trials (β = -0.14, SE = 0.06, t = -2.18, p = 0.032, Table S10 and Figure S1). 
When analyzing the incongruent trials (question iv), there was no significant interaction between 
medication dose and task (BF = 0.22, see Table 3: incongruent trials). 
 
Discussion 
This study investigated automatic imitation and top-down modulation of imitation in schizophrenia. We 
found that patients with schizophrenia, although generally slower, displayed enhanced automatic imitation 
and intact imitation-inhibition compared to matched healthy individuals. The fact that we did not observe 
reduced imitation in schizophrenia stands in marked contrast to previous reports of imitation impairments 
in this patient group. However, previous studies assessed either voluntary imitation7-10, 25-31 or automatic 
imitation of emotional stimuli12, 13, 32, 33 while not controlling for the cognitive, motoric and/or emotional 
deficits associated with the disorder. Thus, it is not possible to assess whether the imitation deficits seen in 
previous studies were primary or secondary to the aforementioned general deficits. By using an imitation 
task with non-emotional stimuli and a control task, we were able to delineate imitation-based effects from 
non-specific cognitive or motoric effects. Indeed, when controlling for these confounders, patients with 
schizophrenia do not display the reduced imitation suggested by previous studies. This finding is in line with 
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imaging and TMS studies showing intact14-17 or even enhanced14, 24 MNS activity in patients during action 
observation or imitation and with work done on social motor coordination in schizophrenia, where 
spontaneous coordination is preserved61.  
It could be argued that the enhanced imitation seen in patients actually reflects over-imitation. Indeed, 
over-imitation is sometimes seen in schizophrenia in the form of symptoms like echolalia or echopraxia31, 32. 
However, there are several factors that suggest that this was not the case. First, patients generally had 
slower RTs. This may have left more room for “improvement” compared to the controls, i.e. the controls 
could not respond much faster than they already were (floor-effect). The association between longer RTs 
and larger imitation effect in the patient group supports this hypothesis. Second, there was an association 
between higher antipsychotic dose and a larger imitation effect even when controlling for potential 
confounders such as symptom severity. This suggests that the enhanced imitation seen may be medication 
induced rather than a consequence of the disorder. Third, the larger the patient’s tendency to imitate, the 
higher the level of functioning was seen. This is opposite to what would be expected if the increased 
imitation indeed reflected a deficit and rather suggests that increased susceptibility to social influence is an 
advantage for the patients. While no patients with symptoms like echolalia and echopraxia were present in 
our sample, we would expect them not to show enhanced imitation, but more likely impaired ability to 
inhibit imitation, consistent with studies on patients with frontal lesions40 which may also display symptoms 
of over-imitation62. Future studies should test this hypothesis in patients displaying such catatonic 
symptoms. 
The association between higher antipsychotic medication dose and increased imitation tendency is 
consistent with findings of increased MNS activity when receiving higher doses of antipsychotic 
medication13 or when being on antipsychotic medication (compared to off)22. In these studies medication 
was associated with activity more similar to that of the healthy controls, suggesting a therapeutic effect. 
The underlying mechanism is not understood. We speculate that it could reflect the oxytocin-enhancing 
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effect of antipsychotics63, 64. Indeed, oxytocin has been shown to enhance MNS activity in healthy 
individuals65, 66 and in patients with schizophrenia67, and to increase imitation68, 69. Future studies could 
explore this relationship further. 
 There are certain limitations of our interpretation. First, 31 out of 33 patients were medicated. It is 
therefore unclear whether unmedicated patients would display similar behaviors as controls. Second, as 
patients were not randomized to different types or doses of antipsychotic medication, we cannot exclude 
that unmeasured individual differences accompanying medication dose contributed to the observed 
effects.  
In conclusion, we did not find reduced imitation in schizophrenia. Rather, patients displayed enhanced 
imitation and intact imitation-inhibition. The enhanced imitation may have been medication induced. The 
results suggest that previous findings of impaired imitation in schizophrenia may have been secondary to 
other cognitive, motoric and/or emotional deficits and that schizophrenia should not be conceptualized as 
a disorder of imitation. These findings could have important implications for how the imitation system 
might be harnessed to facilitate social learning and interaction in patients with schizophrenia, as well as 
contribute to a growing mechanistic model of the social deficits accompanying the disorder.  
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Tables & Figures 
Table 1. Demographic and Clinical Characteristics of Patients and Controls   
  Schizophrenia (n=33) Controls (n=40) 
Age, mean (SD) 36.7 (10.1) 39.3 (10.5) 
No. of males : females 22 : 11 27 : 13 
No. of right : left handed  30 : 3 36 : 4 
Educational level commenced
a
, mean (SD) 2.1 (0.6) 2.3 (0.7) 
Years of education, mean (SD) 12.1 (2.6) 14.4 (3.2) 
No. of high : middle parental SES
b 11 : 22 13 : 27 
Level of functioning (PSP), mean (SD) 57.5 (15.7) 86.1 (5.1) 
Positive symptoms (SAPS)
c
, mean (SD) 4.8 (4.2) - 
Negative symptoms (SANS)
d
, mean (SD) 8.15 (4.9) - 
CPZ equivalent dose in mg, mean (SD) 809 (687) - 
aEducational level commenced divided into 4 levels: 1: primary school (up to 10 years of education), 2: 
secondary school/professional training, 3: bachelor program, 4: master program. bParental socioeconomic 
status (SES) was divided into 3 levels, however none of the parents had a low SES. cSAPS is the total score of 
the 4 global items. It was not possible to obtain a SAPS score for one of the patients. dSANS is the total 
score of the 5 global items.  
 
Table 2. Interaction between group and task on reaction time during i) congruent trials or ii) incongruent 
trials. The two models were defined as: RT = β0i + β1iTask + β2iGroup + β3TaskGroup + ε.  
Factor ß SE t P 
Congruent trials 
Intercept 
 
-0.22 
 
0.05 
 
-4.24 
 
<0.001 
Task -0.09 0.03 -2.48 0.014 
Group 0.39 0.13 2.99 0.005 
Task × Group 
Incongruent trials 
-0.11 0.05 -2.32 0.021 
 
 
Intercept -0.04 0.07 -0.64 0.521 
Task 0.02 0.04 0.63 0.531 
Group 0.48 0.15 3.27 0.001 
Task × Group -0.07 0.05 -1.29 0.195 
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Table 3. Interaction between task and antipsychotic medication dose (CPZ) on reaction time during iii) 
congruent trials or iv) incongruent trials. The two models were defined as: RT = β0i + β1iTask + β2CPZ + 
β3TaskCPZ + ε.  
Factor ß SE t P 
Congruent trials 
Intercept 
 
0.21 
 
0.13 
 
1.65 
 
0.110 
Task -0.20 0.05 -4.17 <0.001 
CPZ 0.17 0.14 1.18 0.245 
Task × CPZ 
Incongruent trials 
-0.13 0.05 -2.47 0.015 
 
Intercept 0.34 0.13 2.68 0.012 
Task -0.04 0.06 -0.76 0.454 
CPZ 0.05 0.15 0.38 0.708 
Task × CPZ 0.09 0.07 1.27 0.215 
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Figure 1. Example of the five frames shown in the imitation task (a) and the three frames shown in the 
control task (b). Both examples are from congruent trials. The first frame in both tasks displayed a resting 
hand that was shown for 800 - 2.400 ms. In the imitation task, the second (34 ms), third (34 ms) and fourth 
frame (500 ms) displayed the number 1 or 2 between the two fingers and the lifting movement of one of 
the fingers. In the control task, the second frame displayed the number 1 or 2 between the two fingers and 
one of the fingers was covered by a mask (display time: 568 ms). The last frame in both tasks was a blue 
screen, which remained on the screen until the participant had placed both fingers back on the keyboard. 
In both tasks, this blue screen appeared when the participant lifted the finger. Reprinted from Cook & Bird 
(2012)70. 
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Figure 2. Mean reaction times (RTs) during congruent (a) and incongruent trials (b) in the imitation and 
control tasks for each group. Error bars: ±1 standard error of the mean (SE).  
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Supplementary Material 
 
 
Table 1S. Chlorpromazine (CPZ) 100 mg/day dose equivalency 
Antipsychotic medication 
mg per 
day/injection  no. of patientsd 
Oral 
 
  
Amisulpride
c 
116.3 1 
Aripiprazole
b 
4 10 
Chlorprothixene
c 
83.3 2 
Clozapine
c 
66.7 5 
Olanzapine
b 
3 9 
Quetiapine
b 
60 6 
Risperidone
b 
0.8 2 
Zuclopenthixol
c 
8.3 3 
Depot
a 
 
  
Paliperidone
b 
15 2 
Perphenazine decanoate
c 
41.4 1 
Risperidone
b 
10 3 
Zuclopenthixol decanoate
c 
66.4 3 
 
a
Depot antipsychotics were first converted to oral equivalencies of the same drug using suggested equivalencies 
based on studies of oral to depot switch
1
 or manufacturer’s recommendation
2, 3
 and then converted to CPZ 
equivalents (see note 
b
 and 
c
). For perphenazine decanoate we used the average minimum effective dose of 
perphenazine decanoate
4
 and equated it with the lowest recommended target dose of oral perphenazine
5
 and then 
converted to CPZ equivalents (see note 
c
).
 b
For the second-generation antipsychotics, we used Leucht et al. (2014)
6
 
to convert to CPZ equivalents when possible except for clozapine where the conversion result was highly 
questionable. 
c
For other antipsychotics (including clozapine), we used Gardner et al. (2010)
5
 to convert to CPZ 
equivalents. 
d
Seventeen patients were taking one antipsychotic, 12 were taking two, two were taking three. Twenty-
seven patients had been on a stable dose for at least 3 weeks prior to the day of testing, while four patients had 
adjustments made (one patient discontinued use of the second and third antipsychotic, two had a down-regulation 
of dose, and one had an up-regulation of dose). 
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Models and Implementation 
 
All analyses were performed with mixed effects regression models (also called multilevel or hierarchical regression 
models). We chose to use mixed effects models because of their flexibility in dealing with complex 
interdependencies in the data (e.g. participant matching, repeated measures by participant), as well as robustness in 
dealing with unbalanced and missing data. Mixed effects models combine fixed effects (analogous to traditional 
statistical predictors) and random effects, that is, effects that are allowed to vary e.g. by participant. In other words, 
participants are not assumed to display the same effects, e.g. by experimental condition, but might display different 
effects. Random effects are partially pooled, that is, a common underlying distribution is assumed, which partially 
constrains the possible variability of individual participants, and can further be used to compensate for unbalanced 
and missing data (for in depth discussion of these issues and a mathematical formalization, see:
7-9
. In order to 
determine the most appropriate regression family and link for the analyses of reaction time (RT), we performed a 
comparative distributional fit analysis of the RT by participant, comparing Gaussian, log-linear and gamma 
distributional fits to the data using Bayesian Information Criterion. Since no distribution was significantly better than 
the Gaussian distribution, we chose to employ linear mixed effects regressions (post-hoc we tested log-linear and 
gamma mixed effects regressions and obtained analogous results to those we reported in the paper). When 
Table 2S   
Medication type no. of patients 
Antidepressant 10 
Anticholinergic 7 
Corticosteroid 6 
Anticonvulsant 4 
Hormonal contraceptive 4 
Proton pump inhibitor 4 
Benzodiazepine (BDZ) 3 
NSAID 3 
Simvastatin 3 
Antibiotic 2 
Antidiabetic 2 
Melatonin 2 
Antabus (Disulfiram) 1 
Antifungal 1 
Anxiolytic non-BDZ 1 
Betablocker 1 
Levothyroxine 1 
Opioid 1 
Paracetamol 1 
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analyzing errors, we used Poisson regression with a log link (count variable).  Analyses were performed in R 3.4.1
10
 
using lme4 1.1-13
11
. Residuals were assessed with DHARMa
12
. Influential data points were checked with leave-one-
out diagnostics
13
. When the groups were compared, the binary variable group (control vs. schizophrenia) was 
included as a fixed effect in addition to the task relevant variable.   
The statistical models explicitly accounted for the one-to-one matching of patients and controls, when present. Each 
pair and unmatched participant was given a common identifier and included as random intercept in the model. This 
allowed us to include unmatched participants and rely on the additional data to reduce uncertainty in the 
estimates
7
. Crucially, we allowed the tightness of the match to vary; that is, we did not assume all one-to-one 
matches to be exactly the same across pairs. We did so by including a random slope for group on the pair random 
intercept. This procedure explicitly estimates the within-pair level of non-independence introduced by matching and 
adjusts standard errors accordingly, which is a more conservative procedure than just assuming homogeneous 
matches. Analogously, we included random slopes for congruency and task, when present in the model, and for 
finger (index vs. middle finger). 
To minimize convergence issues in the estimation of the models, we centered and scaled all linear continuous 
variables. If convergence issues still happened, we simplified the random structure removing one random slope at a 
time until model estimation converged. Full model specifications and parameter estimates for each analysis are 
reported in full in Tables 2 and 3 in the paper as well as 4S to 10S.  Note, that effect sizes are reported in the form of 
standardized beta per each predictor for all linear models. Standardized beta coefficients indicate effect sizes in 
terms of standard deviations (so, for instance, in case of a binomial predictor such as group, they become equivalent 
to Cohen’s d) when controlling for all other predictors included in the model. By reporting standardized effect sizes, 
we make it easier to comparatively assess the effects of different predictors (which are often on different scales). 
Note, for the binomial variable Group, healthy controls were set as baseline; i.e., the effects of group are to be 
interpreted as the difference between patients with schizophrenia and controls, with positive beta values indicating 
higher outcome values for patients compared to controls and negative beta values indicating lower outcome values. 
This also means that beta values of the intercept and other predictors (e.g. Task) are to be interpreted as effects for 
the control group. Similarly, the control task was set as baseline for the Task variable and congruent trials as baseline 
for the Congruency variable. 
In case of null results on theoretically relevant questions, we performed a follow-up Bayes Factor (BF) analysis to 
assess the evidence in favour of the null model. We followed the procedure in Rouder and Morey (2012) for linear 
models with mixed effects (BayesFactor 0.9.12-2.) which employs Liang uninformative priors
14, 15
. A BF below 0.33 
was interpreted as substantial evidence in favour of the null hypothesis, a BF above 3 as substantial evidence in 
favour of the alternative hypothesis, with values below 1 and approaching 0.33 favouring the null over the 
alternative and vice versa. Values close to 1 did not favour one over the other
16, 17
. 
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Table 3S – Mean (SD) number of errors for each condition within each group, distinct by error type: miss (the wrong 
finger was lifted), short (RTs < 150 ms), long (RTs > 2000 ms). Error analyses for each type of error separately 
revealed similar patterns as the reaction time analyses with no significant differences between groups when 
comparing different conditions (results not shown). 
 Imitation Task 
Congruent 
Imitation Task 
Incongruent 
Control Task 
Congruent 
Control Task 
Incongruent 
Controls (Miss) 
Schizophrenia (Miss) 
Controls (Short) 
0.50 (0.68) 
1.39 (1.46) 
0.62 (1.03) 
1.43 (1.57) 
2.32 (2.41) 
0.55 (0.90) 
0.57 (0.96) 
1.00 (1.04) 
0.60 (1.06) 
1.10 (1.39) 
2.11 (1.96) 
0.82 (1.17) 
Schizophrenia (Short) 1.89 (2.46) 1.63 (2.58) 2.00 (2.77) 1.53 (2.33) 
Controls (Long) 0.50 (0.78) 1.02 (0.95) 0.48 (0.82) 1.20 (1.26) 
Schizophrenia (Long) 0.66 (0.78) 1.47 (1.52) 0.97 (1.05) 1.45 (1.22) 
 
Imitation and Effector Priming Control Task 
To assess whether the tasks worked as expected, i.e. incongruent trials resulted in longer RTs than congruent trials, 
we compared RTs in the two conditions (incongruent, congruent) for the imitation task and the control task 
separately across all participants. This was indeed the case: incongruent vs. congruent trials in healthy individuals in 
the imitation task β = 0.33, SE = 0.04, t = 8.55, p < 0.001, Table 4S) and the control task β = 0.19, SE = 0.04, t = 4.74, p 
< 0.001, Table 5S). This relationship was similar for both groups, i.e. the group by congruency interaction was not 
significant and there was substantial evidence in favor of the null-hypothesis of no group difference both within the 
imitation and the control task (ps ≥ 0.12, BFs < 0.15, see Table 4S and 5S). 
 
Table 4S – Interaction between group and congruency on reaction time during imitation trials. The model was 
defined as: RT = β0i + β1iCongruency + β2iGroup + β3CongruencyGroup + ε , where βs are the regression coefficients 
and the subscript i indicates that they are allowed to partially vary by participant pair (or participant when analyzing 
data from one group only) – in other words, that they are included as both fixed effects and random slopes by 
participant pair - and ε is the error term. Note that in this model and in all the following ones correlations between 
random effects were explicitly modelled and estimated. We do not include the correspondent covariance matrix 
within the model equations reported to avoid unnecessarily complicating them. 
Factor ß SE t p 
Intercept -0.30 0.06 -4.84 <0.001 
Congruency 0.33 0.04 8.56 <0.001 
Group 0.36 0.14 2.65 0.012 
Congruency × Group 0.08 0.05 1.54 0.125 
 
 
 
Table 5S – Interaction between group and congruency on reaction time during control trials. The model was defined 
as: RT = β0i + β1iCongruency + β2iGroup + β3CongruencyGroup + ε.  
Factor ß SE t p 
Intercept -0.24 0.05 -4.54 <0.001 
Congruency 0.19 0.04 4.74 <0.001 
Group 0.43 0.13 3.29 0.002 
Congruency × Group 0.02 0.05 0.41 0.68 
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Table 6S – Interaction between mean RT (in the congruent control trials) and task on reaction time during congruent 
trials in the schizophrenia group. The model was defined as: RT = β0i + β1iTask + β2iMeanRT + β3TaskMeanRT + ε.   
Factor ß SE t p 
Intercept 0.44 0.03 13.92 <0.001 
Task -0.25 0.05 -4.60 <0.001 
Mean RT 1.09 0.05 23.91 <0.001 
Task × Mean RT -0.25 0.08 -3.22 0.002 
 
 
Table 7S – Interaction between mean RT (in the congruent control trials) and task on reaction time during congruent 
trials in the control group. The model was defined as: RT = β0i + β1iTask + β2iMeanRT + β3TaskMeanRT + ε.   
Factor ß SE t p 
Intercept 0.02 0.02 0.85 0.393 
Task -0.06 0.04 -1.48 0.143 
Mean RT 1.08 0.06 17.11 <0.001 
Task × Mean RT 0.07 0.10 0.65 0.518 
 
Table 8S – Interaction between antipsychotic dose and task on reaction time during congruent trials, when adjusting 
for other medications and excluding patients who had antipsychotic medication changes within 3 weeks prior to the 
day of testing. The model was defined as: RT = β0i + β1iTask + β2CPZ + β3Antidepressant + β4Anticholinergic + 
β5Corticosteriod + β6Proton-pump-inhibitor + β7Contraception + β8Anticonvulsant + β9NSAID + β10Benzodiazepine 
+ β11Simvastatin + β12TaskCPZ + β13TaskAntidepressant + β14TaskAnticholinergic + β15TaskCorticosteriod + 
β16TaskProton-pump-inhibitor + β17TaskContraception + β18TaskAnticonvulsant + β19TaskNSAID + 
β20TaskBenzodiazepine + β21TaskSimvastatin + ε. Only medications taken by at least three patients were included in 
the model. 
 Factor ß SE t p 
Intercept 0.41 0.21 1.93 0.064 
Task -0.20 0.09 -2.30 0.024 
CPZ 0.15 0.16 0.92 0.368 
Antidepressant -0.12 0.28 -0.43 0.673 
Anticholinergic -0.60 0.36 -1.69 0.101 
Corticosteroid -0.22 0.39 -0.57 0.573 
Proton pump inhib. -0.61 0.44 -1.41 0.171 
Contraception -0.22 0.39 -0.57 0.573 
Anticonvulsant 0.61 0.46 1.33 0.194 
NSAID 0.12 0.49 0.24 0.811 
Benzodiazepine 0.78 0.49 1.61 0.118 
Simvastatin -0.56 0.46 -1.21 0.236 
Task × CPZ -0.18 0.07 -2.62 0.010 
Task × antidepressant -0.03 0.12 -0.21 0.833 
Task × anticholinergic 0.21 0.15 1.45 0.151 
Task × corticosteroid 0.14 0.16 0.87 0.388 
Task × proton-pump-inh 0.12 0.18 0.65 0.516 
Task × contraception -0.41 0.16 -2.50 0.014 
Task × anticonvulsant -0.01 0.19 -0.07 0.941 
Task × NSAID -0.18 0.21 -0.88 0.382 
Task × benzodiazepine -0.26 0.20 -1.32 0.190 
Task × simvastatin 0.01 0.19 0.05 0.959 
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Table 9S – Interaction between task and antipsychotic dose and symptom severity (SANS, SAPS) on reaction time 
during congruent trials, excluding patients who had antipsychotic medication changes within 3 weeks prior to the day 
of testing. The model was defined: RT = β0i + β1iTask + β2SANS + β3SAPS + β4CPZ + β5TaskSANS + β6TaskSAPS + 
β7TaskCPZ + ε.  
Factor ß SE t p 
Intercept 0.21 0.15 1.46 0.156 
Task -0.21 0.05 -3.80 <0.001 
SANS 0.07 0.20 0.36 0.721 
SAPS -0.02 0.15 -0.15 0.881 
CPZ 0.14 0.18 0.78 0.444 
Task × SANS 0.07 0.08 0.97 0.340 
Task × SAPS -0.01 0.06 -0.25 0.801 
Task × CPZ -0.17 0.07 -2.47 0.020 
 
 
Table 10S – Interaction between task and antipsychotic dose and level of functioning (PSP) on reaction time during 
congruent trials, excluding patients who had antipsychotic medication changes within 3 weeks prior to the day of 
testing. The model was defined: RT = β0i + β1iTask + β2PSP + β3CPZ + β4TaskPSP + β5TaskCPZ + ε.  
Factor ß SE t p 
Intercept 0.25 0.20 1.22 0.234 
Task -0.33 0.07 -4.46 <0.001 
PSP 0.06 0.18 0.31 0.757 
CPZ 0.19 0.17 1.10 0.282 
Task × PSP -0.14 0.06 -2.18 0.032 
Task × CPZ -0.19 0.06 -3.05 0.003 
 
 
Figure 1S. Marginal relation between imitation (compared to the control condition) on the x-axis and level of 
functioning (PSP) on the y-axis after controlling for antipsychotic medication dose. Note, the negative values on the 
x-axis indicate faster reaction times to the imitation task compared to the control task. Marginal effects were 
estimated following Fox (2003)
18
.   
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